000			03069na a2200409 4500
999			_c7261 _d7261
003			PC7261
005			20210625062805.0
008			130622s2013 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aAgudo López, Alba _92394 _eInstituto de Investigación i+12
100			_aAgulló Ortuño, María Teresa _91791 _eOncología Médica
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aCortijo, Ana _92398 _eOncología Médica
100			_aDíaz García, C. Vanesa _92396 _eInstituto de Investigación i+12
100			_aIglesias Docampo, Lara _91919 _eOncología Médica
100			_aLópez Martín, José Antonio _91797 _eOncología Médica
100			_aMartínez Villanueva, Miriam _92397 _eOncología Médica
100			_aPérez, Carlos _92395 _eInstituto de Investigación i+12
100			_aRodríguez Peralto, José Luis _91219 _eAnatomía Patológica
245	0	0	_aDICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. _h[artículo]
260			_bCarcinogenesis, _c2013
300			_a34(5):1031-8.
500			_aFormato Vancouver: Díaz-García CV, Agudo-López A, Pérez C, López-Martín JA, Rodríguez-Peralto JL, de Castro J et al. DICER1, DROSHA and miRNAs in patients with non-small cell lung cancer: implications for outcomes and histologic classification. Carcinogenesis. 2013 May;34(5):1031-8.
501			_aPMID: 23349018
504			_aContiene 37 referencias
520			_aThe clinical and functional significance of RNA-interference machinery in lung cancer is poorly understood. Besides, microRNAs (miRNA) have the potential to serve both as biomarkers and therapeutic agents, by personalizing diagnosis and therapy. In this study, we investigated whether the expression levels of DICER1 and DROSHA, components of the RNA-interference machinery, can predict survival, and whether the miRNA expression profiles can differentiate histologic subtypes in non-small cell lung cancer (NSCLC). Levels of DICER1, DROSHA and five different miRNAs were measured in NSCLC specimens (N = 115) by qRT-PCR assay and correlated with clinical outcomes. Low expression of DROSHA was associated with an increased median survival (154.2 versus 39.8 months, P = 0.016). Also, high DROSHA expression was associated with decreased median survival in the following subgroups: adenocarcinoma (P = 0.011), grade III tumors (P = 0.038) and low-stage patients (P = 0.014). In multivariate analyses, we found two independent predictors of reduced disease-specific survival: high DROSHA expression [hazards ratio = 2.24; P = 0.04] and advanced tumor stage (hazards ratio = 1.29, P = 0.02). In general, the overall tumor miRNA expression was downregulated in our cohort compared with normal tissues. Expression levels of hsa-let-7a (P = 0.005) and miR-16 (P = 0.003) miRNA were significantly higher in squamous cell carcinoma than in adenocarcinoma samples. This study supports the value of the expression profiling of the components of the miRNA-processing machinery in the prognosis of NSCLC patients, especially DROSHA expression levels. In addition, differential expression of miRNAs, such as hsa-let-7a and miR-16 may be helpful tools in the histologic subclassification of NSCLC.
710			_9303 _aServicio de Oncología Médica
710			_9330 _aServicio de Anatomía Patológica
710			_9625 _aInstituto de Investigación imas12
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/7/pc7261.pdf _ySolicitar documento
942			_n0 _2ddc _cART